HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Activity All Versions of this Article: jnumed.106.037689v1 48/9/1468    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, W. Search for Related Content PubMed PubMed Citation Articles by Chen, W.

Clinical Applications of PET in Brain Tumors^*

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; and Department of Radiology, Kaiser Permanente Woodland Hills Medical Center, Woodland Hills, California

Correspondence: For correspondence or reprints contact: Wei Chen, MD, PhD, CHS, AR-144, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095. E-mail: weichen{at}mednet.ucla.edu

Malignant gliomas and metastatic tumors are the most common brain tumors. Neuroimaging plays a significant role clinically. In low-grade tumors, neuroimaging is needed to evaluate recurrent disease and to monitor anaplastic transformation into high-grade tumors. In high-grade and metastatic tumors, the imaging challenge is to distinguish between recurrent tumor and treatment-induced changes such as radiation necrosis. The current clinical gold standard, MRI, provides superior structural detail but poor specificity in identifying viable tumors in brain treated with surgery, radiation, or chemotherapy. ¹⁸F-FDG PET identifies anaplastic transformation and has prognostic value. The sensitivity and specificity of ¹⁸F-FDG in evaluating recurrent tumor and treatment-induced changes can be improved significantly by coregistration with MRI and potentially by delayed imaging 3–8 h after injection. Amino acid PET tracers are more sensitive than ¹⁸F-FDG in imaging recurrent tumors and in particular recurrent low-grade tumors. They are also promising in differentiating between recurrent tumors and treatment-induced changes.

Key Words: neurology • oncology • PET • brain • tumors

Guest Editor: H. William Strauss, Memorial Sloan-Kettering Cancer Center

^* NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ACTIVITY THROUGH THE SNM WEB SITE (http://www.snm.org/ce_online) THROUGH SEPTEMBER 2008.

No potential conflict of interest relevant to this article was reported.

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11A-12A. [Full Text]  

This article has been cited by other articles:

				P. Y. Wen and S. Kesari Malignant Gliomas in Adults N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507. [Full Text] [PDF]

				Y. Terakawa, N. Tsuyuguchi, Y. Iwai, K. Yamanaka, S. Higashiyama, T. Takami, and K. Ohata Diagnostic Accuracy of 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy J. Nucl. Med., May 1, 2008; 49(5): 694 - 699. [Abstract] [Full Text] [PDF]

				A. A. Brandes, A. Tosoni, F. Spagnolli, G. Frezza, M. Leonardi, F. Calbucci, and E. Franceschi Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology Neuro-oncol, January 1, 2008; 10(3): 361 - 367. [Abstract] [Full Text] [PDF]